Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Johnson & Johnson (JNJ) Faces Competition From Mylan NV (MYL) Concerta Knockoff

While the US Food and Drug Administration (FDA) has recently kicked out knockoff versions of Concerta, the attention deficit hyperactivity disorder (ADHD) drug from Johnson & Johnson (NYSE:JNJ) manufactured and commercialized by Lannett Company, Inc. (NYSE:LCI) and Mallinckrodt PLC (NYSE:MNK), the company is facing more competition with the recent approval of the knockoff version from Mylan NV (NASDAQ:MYL).

Concerta Competitor

According to Umer Raffat, an Evercore ISI analyst, it appears that the FDA has approved the new Concerta competitor from Mylan with an AB rating. Should this be the case, it would be the first Concerta knockoff to get a coveted distinction from the FDA. This distinction means that the drug is an efficient substitute for the branded counterpart from Johnson & Johnson (NYSE:JNJ).

care, pharmacist, business, pill, chemist, clinic, drugstore, medicine, illness, health, indoors, prescription, healthcare, pharmaceutical, medical, retail, drug, singapore, treatment, shelf, medication, hospital, store, shop, pharmacy

Trong Nguyen /

While Mylan NV (NASDAQ:MYL) is not widely expected to lead the Concerta—branded and generic— market, it is believed that it will get a bigger market share than Lannett and Mallinckrodt. Needless to say, this will affect the Concerta revenue for Johnson and Johnson.

The approval of its version of Concerta will give Mylan a much needed boost, especially at a time when it is embattled by the price hikes of EpiPen.

Follow Mylan N.v. (NASDAQ:MYL)
Trade (NASDAQ:MYL) Now!

Booting Other Concerta Knockoffs

The FDA found out post-approval that the generic versions of Concerta from Lannett and Mallinckrodt wear off quicker than Concerta. The two companies have failed to prove the meaningful efficacy of the generic medicines within the timeframe given by the FDA. As a result, both drugs were denied approval for commercialization last week.

Analysts suspect that the timing of the two Concerta copies and approving the generic version from Mylan is not coincidental.

“We suspect the FDA wanted to ensure supply of the product before moving to remove the BX-rated products,” explained Douglas Tsao and Morgan Williams, Barclays analysts.

On Wednesday, Johnson & Johnson (NYSE:JNJ) has surged 0.53% to $114.56; Lannett has declined 2.51% to $21.40; Mallinckrodt has jumped 0.33% to $62.87; and Mylan NV (NASDAQ:MYL) has lost 1.55% to $38.08.

Follow Johnson & Johnson (NYSE:JNJ)
Trade (NYSE:JNJ) Now!

Note: This article is written by Adam Russell and originally published at Market Exclusive.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.